Medication topics
Infliximab articles covering Remicade, Inflectra, Renflexis, Avsola, Zymfentra, anti-TNF therapy, safety, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 2 · 64 articles
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a...
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology and...
Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
